

Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form



Fax Referral To: 1-888-280-1191
Phone: 1-888-280-1190
Email Referral To: PAH.faxes@caremark.com

Fax Referral To: 787-759-4161
Phone: 787-759-4162
Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name: _____ DOB: _____
Address: _____ City, State, ZIP Code: _____
Gender: Male Female
Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below)
Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.
Primary Phone: _____ Alternate Phone: _____
If **Minor**, Parent/Caregiver/Guardian Name (Last, First): _____
Relationship to minor: _____
Email: _____ Last Four of SSN: _____ Primary Language: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____
NPI #: _____ DEA #: _____ Group or Hospital: _____
Address: _____ City, State, ZIP Code: _____
Phone: _____ Fax: _____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Ship to: Patient Office Other: _____

Diagnosis (ICD-10):

Date of Diagnosis: _____
 I27.0 Primary Pulmonary Hypertension I27.20 Pulmonary Hypertension, Unspecified
 I27.21 Secondary Pulmonary Arterial Hypertension I27.24 Chronic Thromboembolic Pulmonary Hypertension
 I27.83 Eisenmenger's Syndrome I27.89 Other Specified Pulmonary Disease
 Other Code: _____ **Description:** _____

Patient Clinical Information:

New York Heart Association (NYHA) Functional Classification: I II III IV
6 Minute Walk Distance: _____ meters
Is patient currently on another therapy for pulmonary hypertension? Yes No
If Yes, name of drug(s): _____

Weight: _____ lb/kg Height: _____ in/cm Allergies: _____

Attach copies of: History and Physical Right Heart Catheterization Calcium Channel Blocker Statement Echocardiogram

Nursing: Not Needed Pre-hospital/Pre-home Teaching In-hospital Teaching Nursing Follow-up

Start of care date: _____ **Number of visits:** _____

Prostacyclin Referral Information:

Check the boxes below to designate which items are included in this fax:

- PAH diagnosis and ICD-10 code (designated on PAH referral form)
Is Medicare Part B the primary insurance for this referral? Yes No
 Clinical documentation
 Current H&P (within 6 months); Date of H&P: _____
 Right Heart Catheterization (RHC); Check below if included in the RHC report
 Mean PA Pressure (or systolic/diastolic) > 25 mmHg at rest or > 30 mmHg with exertion
 Cardiac Output Cardiac Index
 Pulmonary Vascular Resistance Pulmonary Capillary Wedge Pressure (or LVEDP) < 15 mmHg
 Echocardiogram
 Calcium Channel Blocker statement with supporting documentation
 Patients with the following disease states will require documentation that the PAH is out-of-proportion with the secondary disease: Left heart disease, valvular heart disease, lung disease, sarcoidosis and other co-morbidities, except for the ones listed in WHO Group I category

Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form

Tyvaso, Ventavis, Flolan, Epoprostenol (Generic Flolan), Remodulin

Please Complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____

Prescriber Name: _____ Prescriber Phone: _____

5 PRESCRIPTION INFORMATION

INHALED PRODUCTS:

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Tyvaso (treprostinil) Inhalation Solution	<input type="checkbox"/> Tyvaso Inhalation System Starter Kit <input type="checkbox"/> Tyvaso Refill Kit	<input type="checkbox"/> Start with 3 breaths (18 mcg) four times daily. Increase by 3-4 breaths at 1-2 week intervals, if tolerated, until the target dose of 9 breaths (54 mcg) four times daily. <input type="checkbox"/> Other: _____	Quantity: 28-day supply Refills: _____
<input type="checkbox"/> Ventavis (iloprost) Inhalation Solution	NA	Please complete a Ventavis enrollment form and indicate CVS Specialty as your preferred pharmacy provider. The form may be accessed at www.4ventavis.com or by calling 1-866-228-3546.	Quantity: 0 Refills: 0

INFUSED THERAPIES:

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Flolan (epoprostenol) for injection	<input type="checkbox"/> 0.5 mg vial <input type="checkbox"/> 1.5 mg vial <input type="checkbox"/> Sterile diluent for Flolan <input type="checkbox"/> pH 12 sterile diluent for Flolan	<input type="checkbox"/> IV infusion continuous over 24 hours Initial dose: _____ ng/kg/min. Titrate by _____ ng/kg/min every _____ days until goal of _____ ng/kg/min achieved. Discharge dose: _____ ng/kg/min Concentration: _____ ng/mL Pump: 2 CADD-Legacy Pumps CVC Care: <input type="checkbox"/> Dressing change every _____ days. <input type="checkbox"/> Per IV standard of care	Quantity: One-month supply of drug and supplies. Dosing weight: _____ kg/lb Refills: _____
<input type="checkbox"/> Epoprostenol (Generic Flolan)	<input type="checkbox"/> 0.5 mg vial <input type="checkbox"/> 1.5 mg vial <input type="checkbox"/> Epoprostenol diluent	<input type="checkbox"/> IV infusion continuous over 24 hours Initial dose: _____ ng/kg/min. Titrate by _____ ng/kg/min every _____ days until goal of _____ ng/kg/min achieved. Discharge dose: _____ ng/kg/min Concentration: _____ ng/mL Pump: 2 CADD-Legacy Pumps CVC Care: <input type="checkbox"/> Dressing change every _____ days. <input type="checkbox"/> Per IV standard of care	Quantity: One-month supply of drug and supplies. Dosing weight: _____ kg/lb Refills: _____
<input type="checkbox"/> Remodulin (treprostinil) for injection	<input type="checkbox"/> 1 mg/mL, 20 mL vial <input type="checkbox"/> 2.5 mg/mL, 20 mL vial <input type="checkbox"/> 5 mg/mL, 20 mL vial <input type="checkbox"/> 10 mg/mL, 20 mL vial	<input type="checkbox"/> SC continuous over 24 hours Initial dose: _____ ng/kg/min. Titrate by _____ ng/kg/min every _____ days until goal of _____ ng/kg/min achieved. Change infusion site every _____ days. Palliative med PRN _____ Pumps: 2 CADD-MS3 pumps <input type="checkbox"/> IV infusion continuous over 24 hours Initial dose: _____ ng/kg/min. Titrate by _____ ng/kg/min every _____ days until goal of _____ ng/kg/min achieved. Diluent: Check one (Sterile diluent for Remodulin will be used if no box is checked) <input type="checkbox"/> 0.9% NaCl for injection <input type="checkbox"/> Sterile Water for injection <input type="checkbox"/> Epoprostenol Sterile diluent <input type="checkbox"/> Sterile diluent for Remodulin Pump: <input type="checkbox"/> 2 CADD-Legacy Pumps <input type="checkbox"/> 2 CADD-MS 3 Pumps CVC Care: <input type="checkbox"/> Dressing change every _____ days. <input type="checkbox"/> Per IV standard of care	Quantity: One-month supply of drug and supplies. Dosing weight: _____ kg/lb Refills: _____

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute

Prescriber's Signature: _____ Date: _____

May Substitute / Product Selection Permitted / Substitution Permissible

Prescriber's Signature: _____ Date: _____

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. ©2022 CVS Specialty and/or one of its affiliates. 75-41534A 03/28/22

Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form

Treprostinil (Generic Remodulin), Veletri, Epoprostenol (Generic Veletri)

Please Complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____
 Prescriber Name: _____ Prescriber Phone: _____

5 PRESCRIPTION INFORMATION

INFUSED THERAPIES CONTINUED:

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Treprostinil (Generic Remodulin)	<input type="checkbox"/> 1 mg/mL, 20 mL vial <input type="checkbox"/> 2.5 mg/mL, 20 mL vial <input type="checkbox"/> 5 mg/mL, 20 mL vial <input type="checkbox"/> 10 mg/mL, 20 mL vial	<input type="checkbox"/> IV infusion continuous over 24 hours Initial dose: _____ ng/kg/min. Titrate by _____ ng/kg/min every ____ days until goal of _____ ng/kg/min achieved. <u>Diluent:</u> Check one (Sterile diluent for Treprostinil will be used if no box is checked) <input type="checkbox"/> 0.9% NaCl for injection <input type="checkbox"/> Sterile Water for injection <input type="checkbox"/> Epoprostenol Sterile diluent <input type="checkbox"/> Sterile diluent for Treprostinil Pump: 2 CADD-Legacy Pumps <u>CVC Care:</u> <input type="checkbox"/> Dressing change every ____ days. <input type="checkbox"/> Per IV standard of care	Quantity: One-month supply of drug and supplies. Dosing weight: _____ kg/lb Refills: _____
<input type="checkbox"/> Veletri (epoprostenol) for injection	<input type="checkbox"/> 0.5 mg vial <input type="checkbox"/> 1.5 mg vial	<input type="checkbox"/> IV infusion continuous over 24 hours Initial dose: _____ ng/kg/min. Titrate by _____ ng/kg/min every ____ days until goal of _____ ng/kg/min achieved. Discharge dose: _____ ng/kg/min Concentration: _____ ng/mL <u>Diluent:</u> Check one (0.9% Sodium Chloride will be used if no box is checked) <input type="checkbox"/> 0.9% NaCl for injection <input type="checkbox"/> Sterile Water for injection Pump: 2 CADD-Legacy Pumps <u>CVC Care:</u> <input type="checkbox"/> Dressing change every ____ days. <input type="checkbox"/> Per IV standard of care	Quantity: 30-day supply of drug and supplies. Dosing weight: _____ kg/lb Refills: _____
<input type="checkbox"/> Epoprostenol (Generic Veletri)	<input type="checkbox"/> 0.5 mg vial <input type="checkbox"/> 1.5 mg vial	<input type="checkbox"/> IV infusion continuous over 24 hours Initial dose: _____ ng/kg/min. Titrate by _____ ng/kg/min every ____ days until goal of _____ ng/kg/min achieved. Discharge dose: _____ ng/kg/min Concentration: _____ ng/mL <u>Diluent:</u> Check one (0.9% Sodium Chloride will be used if no box is checked) <input type="checkbox"/> 0.9% NaCl for injection <input type="checkbox"/> Sterile Water for injection Pump: 2 CADD-Legacy Pumps <u>CVC Care:</u> <input type="checkbox"/> Dressing change every ____ days. <input type="checkbox"/> Per IV standard of care	Quantity: 30-day supply of drug and supplies. Dosing weight: _____ kg/lb Refills: _____

Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates. ©2022 CVS Specialty and/or one of its affiliates. 75-41534A 03/28/22 Page 3 of 3